Neurology

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

In contrast, men did not face the same increased risk of cerebrovascular disease later in life, reported authors of a new study.

The FDA has assigned a PDUFA action date of January 25, 2025 for the monthly IV maintenance dose.

From top barriers in seeking treatment to how well mental health issues are identified and treated, find out what US adults really think about the mental health care system.

The AdComm plans to review data from the TRAILBLAZER-ALZ 2 phase 3 clinical trial that served as the foundation for Eli Lilly's original BLA submission to the FDA.

Study participants who had a history of stroke were nearly 60% less likely to meet guideline-recommended secondary prevention goals, new research reveals.

The CLEAR Outcomes PI explains the patient selection approach for bempedoic acid, now approved to reduce risk of CV events in addition to lowering LDL-C.

Tirzepatide reduced OSA symptoms and body weight in study participants with severe OSA and obesity, regardless of use of positive airway pressure therapy.

Labeling for triptan medications warns of potential for ischemic events but is the concern theoretical or real? A new study tests the association.

AAN: 70% of participants reached ≥50% reduction in MMDs at weeks 13-16 that was consistent for 48 weeks in an interim analysis of a 156-week open-label trial.

The AHS recommends the migraine-specific preventive medications be prescribed first, with no requirements to "fail" other treatments for eligibility.

Your daily dose of the clinical news you may have missed.

Migraine was the most important nontraditional risk factor linked to stroke in adults aged 18 to 34 years and should be considered in evaluation for an event.

Atogepant was associated with fewer monthly migraine days, fewer acute medication use days, and greater QoL compared with rimegepant after 12 weeks.

The phase 4 APPRAISE trial found greater efficacy with erenumab after failure with 1 or 2 other preventives vs ongoing treatment with the nonspecific oral agents.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Even activity levels considered "insufficient" by guideline standards were found protective against stroke in this new systematic review and meta-analysis.

A man in his eighties presents to the ED after 1 week of persistent bilateral leg weakness and dysgeusia that has not worsened. What's your Dx?

Your daily dose of the clinical news you may have missed.

The surprise request for review of the phase 3 TRAILBLAZER-ALZ-2 clinical trial findings will delay the original PDUFA timing beyond first quarter 2024.

Patients who had microplastics and nanoplastics in their carotid plaque were at more than a fourfold risk for MI, stroke, or death compared to those who did not, according to a new study.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.